Skip to content
Accessible Unlicensed Requires Authentication Published by De Gruyter September 21, 2011

A common CYP1B1 polymorphism is associated with 2-OHE1/16-OHE1 urinary estrone ratio

Valentina Paracchini, Paola Pedotti, Sara Raimondi, Seymour Garte, H. Leon Bradlow, Daniel W. Sepkovic and Emanuela Taioli


Cytochrome P450 (CYP) is a multigene family of enzymes involved in important life functions; some of these genes are inducible and are implicated in the oxidative metabolic activation and detoxification of many endogenous and exogenous compounds. CYP1B1 codes for an enzyme that catalyses the production of a 2- and 4-hydroxyl group in estrone and estradiol, while CYP1A1 catalyzes the 2-hydroxylation of estradiol in endometrium. The two genes were evaluated in a cohort of 150 subjects: African-American women had significantly lower 2-hydroxyl estrone/16-hydroxyl estrone (2-OHE1/16-OHE1) urinary metabolite ratios than Caucasian women (2.06±1.05 vs. 1.43±0.56; p=0.0002). A common polymorphism in the CYP1B1 gene (leucine to valineat codon 432) was associated with changes in urinary estrogen levels: both Caucasian and African-American women carrying the variant allele showed higher urinary metabolite ratios than women with the wild-type allele. No effect of the CYP1A1 MspI was observed. The 4-OHE1/2-OHE1 ratio was lower in subjects carrying the variant allele (Leu). The percentage change in 2-OHE1/16-OHE1 urinary ratio after indole treatment was significant in both Caucasian and African-American women carrying the wild-type CYP1B1 genotype, although it was more evident in African-Americans than in Caucasians. These results suggest that the Leu/Val CYP1B1 polymorphism may modify estradiol metabolism.

Corresponding author: Emanuela Taioli, MD PhD, Molecular and Genetic Epidemiology Unit, Fondazione Ospedale Policlinico IRCCS, Palazzina Bertarelli, Via Pace 9, 20122 Milano, Italy Phone/Fax: +39-02-55034055,


1. Nebert DW, Russell DW. Clinical importance of the cytochromes P450. Lancet 2002; 12; 360: 1155–62. Search in Google Scholar

2. Lewis DF. 57 varieties: the human cytochromes P450. Pharmacogenomics 2004; 5: 305–18. Search in Google Scholar

3. Gonzalez F. The molecular biology of cytochrome P450s. Pharmacol Rev 1998; 40: 243–88. Search in Google Scholar

4. Guengerich FP, Shimada T. Oxidation of toxic and carcinogenic chemicals by human cytochrome P-450 enzymes. Chem Res Toxicol 1991; 4: 391–407. Search in Google Scholar

5. Shimada T, Hayes CL, Yamazaki H, Amin S, Hecht SS, Guengerich FP, et al. Activation of chemically diverse procarcinogens by human cytochrome P-450 1B1. Cancer Res 1996; 56: 2979–84. Search in Google Scholar

6. Hakkola J, Pasanen M, Pelkonen O, Hukkanen J, Evisalmi S, Anttila S, et al. Expression of CYP1B1 in human adult and fetal tissues and differential inducibility of CYP1B1 and CYP1A1 by Ah receptor ligands in human placental and cultured cells. Carcinogenesis 1994; 15: 997–1000. Search in Google Scholar

7. Hayes CL, Spink DC, Spink BC, Cao JQ, Walker NJ, Sutter TR. 17β-Estradiol hydroxylation catalysed by human cytochrome P450 1B1. Proc Natl Acad Sci USA 1996; 93: 9776–81. Search in Google Scholar

8. Bailey LR, Roodi N, Dupont WD, Parl FF. Association of cytochrome P450 1B1 (CYP1B1) polymorphism with steroid receptor status in breast cancer. Cancer Res 1998; 58: 5038–41. Search in Google Scholar

9. Tang YM, Green BL, Chen GF, Thompson PA, Lang NP, Shinde A, et al. Human CYP1B1 Leu432Val gene polymorphism: ethnic distribution in African-Americans, Caucasians and Chinese: oestradiol hydroxylase activity, and distribution in prostate cancer cases and controls. Pharmacogenetics 2000; 10: 761–6. Search in Google Scholar

10. Hanna IH, Dawling S, Roodi N, Guengerich FP, Parl FF. Cytochrome P450 1B1 (CYP1B1) pharmacogenetics: association of polymorphisms with functional differences in estrogen hydroxylation activity. Cancer Res 2000; 60: 3440–4. Search in Google Scholar

11. Li DN, Seidel A, Pritchard MP, Wolf CR, Friedberg T. Polymorphisms in P450 CYP1B1 affect the conversion of estradiol to the potentially carcinogenic metabolite 4-hydroxyestradiol. Pharmacogenetics 2000; 10: 343–53. Search in Google Scholar

12. Aklillu E, Oscarson M, Hidestrand M, Leidvik B, Otter C, Ingelman-Sundberg M. Functional analysis of six different polymorphic CYP1B1 enzyme variants found in an Ethiopian population. Mol Pharmacol 2002; 61: 586–94. Search in Google Scholar

13. Vadlamuri SV, Glover DD, Turner T, Sarkar MA. Regio-specific expression of cytochrome P4501A1 and 1B1 in human uterine tissue. Cancer Lett 1998; 122: 143–50. Search in Google Scholar

14. Doherty JA, Weiss NS, Freeman RJ, Dightman DA, Thornton PJ, Houck JR, et al. Genetic factors in catechol estrogen metabolism in relation to the risk of endometrial cancer. Cancer Epidemiol Biomarkers Prev 2005; 14: 357–66. Search in Google Scholar

15. Kawajiri K. CYP1A1. Lyon IARC Sci Publ, 1999:159–72. Search in Google Scholar

16. Anttila S, Vainio H, Hietanen E, Camus AM, Malaveille C, Brun G, et al. Immunohistochemical detection of pulmonary cytochrome P4501A and metabolic activities associated with P4501A1 and P4501A2 isozymes in lung cancer patients. Environ Health Perspect 1992; 98: 179–82. Search in Google Scholar

17. Kouri RE, McKinney CE, Slomiany DJ, Snodgrass DR, Wray NP, McLemore TL. Positive correlation between high aryl hydrocarbon hydroxylase activity and primary lung cancer as analyzed in cryopreserved lymphocytes. Cancer Res 1982; 42: 5030–7. Search in Google Scholar

18. Song BJ, Gelboin HV, Park SS, Tsokos GC, Friedman FK. Monoclonal antibody-directed radioimmunoassay detects cytochrome P-450 in human placenta and lymphocytes. Science 1985; 228: 490–2. Search in Google Scholar

19. Yamazaki H, Shaw PM, Guengerich FP, Shimada T. Roles of cytochromes P450 1A2 and 3A4 in the oxidation of estradiol and estrone in human liver microsomes. Chem Res Toxicol 1998; 11: 659–65. Search in Google Scholar

20. Spink DC, Eugster HP, Lincoln DW II, Schuetz JD, Schuetz EG, Johnson JA, et al. 17β-Estradiol hydroxylation catalyzed by human cytochrome P450 1A1: acomparison of the activities induced by 2,3,7,8-tetrachlorodibenzo-p-dioxin in MCF-7 cells with those from heterologous expression of the cDNA. Arch Biochem Biophys 1992; 293: 342–8. Search in Google Scholar

21. Petersen DD, McKinney CE, Ikeya K, Smith. HH, Bale AE, McBride OW, et al. Human CYP1A1 gene: cosegregation of the enzyme inducibility phenotype and an RFLP. Am J Hum Genet 1991; 48: 720–5. Search in Google Scholar

22. Landi MT, Bertazzi PA, Shields PG, Clark G, Lucier GW, Garte SJ, et al. Association between CYP1A1 genotype, mRNA expression and enzymatic activity in humans. Pharmacogenetics 1994; 4: 242–6. Search in Google Scholar

23. Crofts F, Cosma G, Currie D, Taioli E, Toniolo P, Garte SJ. A novel CYP1A1 gene polymorphism in African-Americans. Carcinogenesis 1993; 14: 829–31. Search in Google Scholar

24. Taioli E, Crofts F, Trachman J, Bayo S, Toniolo P, Garte SJ. Radical differences in CYP1A1 genotype and function. Toxicol Lett 1995; 77: 357–62. Search in Google Scholar

25. Kiyohara C, Hirohata T, Inutsuka S. The relationship between aryl hydrocarbon hydroxylase and polymorphisms of the CYP1A1 gene. Jpn J Cancer Res 1996; 87: 18–24. Search in Google Scholar

26. Cosma G, Crofts F, Currie D, Wirgin I, Toniolo P, Garte SJ. Racial differences in restriction fragment lengthpolymorphisms and messenger RNA inducibility of the human CYP1A1 gene. Cancer Epidemiol Biomarkers Prev 1993; 2: 53–7. Search in Google Scholar

27. Jacquet M, Lambert V, Baudoux E, Muller M, Kremers P, Gielen J. Correlation between P450 CYP1A1 inducibility, MspI genotype and lung cancer incidence. Eur J Cancer 1996; 32A: 1701–6. Search in Google Scholar

28. Garte S, Ganguly S, Taioli E. Effect of genotype on steady-state CYP1A1 gene expression in human peripheral lymphocytes. Biochem Pharmacol 2003; 65: 441–5. Search in Google Scholar

29. Kawajiri K, Nakachi K, Imai K, Watanabe J, Hayashi S. The CYP1A1 gene and cancer susceptibility. Crit Rev Oncol Hematol 1993; 14: 77–87. Search in Google Scholar

30. Cosma G, Crofts F, Taioli E, Toniolo P, Garte S. Relationship between genotype and function of the human CYP1A1 gene. J Toxicol Environ Health 1993; 40: 309–16. Search in Google Scholar

31. Zhang ZY, Fasco MJ, Huang L, Guengerich FP, Kaminsky LS. Characterization of purified human recombinant cytochrome P4501A1-Ile462 and -Val462: assessment of a role for the rare allele in carcinogenesis. Cancer Res 1996; 56: 3926–33. Search in Google Scholar

32. Persson I, Johansson I, Ingelman-Sundberg M. In vitro kinetics of two human CYP1A1 variant enzymes suggested to be associated with interindividual differences in cancer susceptibility. Biochem Biophys Res Commun 1997; 231: 227–30. Search in Google Scholar

33. Schwarz D, Kisselev P, Schunck WH, Chernogolov A, Boidol W, Cascorbi I, et al. Allelic variants of human cytochrome P450 1A1 (CYP1A1): effect of T461N and I462V substitutions on steroid hydroxylase specificity. Pharmacogenetics 2000; 10: 519–30. Search in Google Scholar

34. Schwarz D, Kisselev P, Cascorbi I, Schunck WH, Roots I. Differential metabolism of benzo[a]pyrene and benzo[a]pyrene-7,8-dihydrodiol by human CYP1A1 variants. Carcinogenesis 2001; 22: 453–9. Search in Google Scholar

35. Kelly EJ, Adman ET, Eaton DL. Functional significance of the human CYP1A1 m4 polymorphism: relevance to endometrial cancer risk. In: 9th North American ISSX Meeting, Nashville, TN, 1999:Abstract 265. Search in Google Scholar

36. Garte S, Gaspari L, Alexandrie AK, Ambrosone C, Autrup H, Autrup JL, et al. Metabolic gene polymorphism frequencies in control populations. Cancer Epidemiol Biomarkers Prev 2001; 10: 1239–48. Search in Google Scholar

37. Taioli E, Bradlow HL, Garbers SV, Sepkovic DW, Osborne MP, Trachman J, et al. Role of estradiol metabolism and CYP1A1 polymorphisms in breast cancer risk. Cancer Detect Prev 1999; 23: 232–7. Search in Google Scholar

38. Hachey DL, Dawling S, Roodi N, Parl FF. Sequential action of phase I and II enzymes cytochrome p450 1B1 and glutathione S-transferase P1 in mammary estrogen metabolism. Cancer Res 2003; 63: 8492–9. Search in Google Scholar

39. Liehr JG, Fang WF, Sirbasku DA, Ari-Ulubelen A. Carcinogenicity of catechol estrogens in Syrian hamsters. J Steroid Biochem 1986; 24: 353–6. Search in Google Scholar

40. Liehr JG, Ricci MJ. 4-Hydroxylation of estrogens as marker of human mammary tumors. Proc Natl Acad Sci USA 1996; 93: 3294–6. Search in Google Scholar

41. Taioli E, Garte SJ, Trachman J, Garbers S, Sepkovic DW, Osborne MP, et al. Ethnic differences in estrogen metabolism in healthy women. J Natl Cancer Inst 1996; 88: 617. Search in Google Scholar

42. Sepkovic DW, Bradlow HL, Michnovicz J, Murtezani S, Levy I, Osborne MP. Catechol estrogen production in rat microsomes after treatment with indole-3-carbinol, ascorbigen, or beta-naphthaflavone: a comparison of stable isotope dilution gas chromatography-mass spectrometry and radiometric methods. Steroids 1994; 59: 318–23. Search in Google Scholar

43. Davis DL, Bradlow HL, Wolff M, Woodruff T, Hoel DG, Anton-Culver H. Medical hypothesis: xenoestrogens as preventable causes of breast cancer. Environ Health Perspect 1993; 101: 372–7. Search in Google Scholar

44. Bradlow HL, Davis DL, Lin G, Sepkovic D, Tiwari R. Effects of pesticides on the ratio of 16 alpha/2-hydroxyestrone: a biologic marker of breast cancer risk. Environ Health Perspect 1995; 103(Suppl 7): 147–50. Search in Google Scholar

45. Shimada T, Watanabe J, Kawajiri K, Sutter TR, Guengerich FP, Gillam EM, et al. Catalytic properties of polymorphic human cytochrome P450 1B1 variants. Carcinogenesis 1999; 20: 1607–13. Search in Google Scholar

46. Watanabe J, Shimada T, Gillam EM, Ikuta T, Suemasu K, Higashi Y, et al. Association of CYP1B1 genetic polymorphism with incidence to breast and lung cancer. Pharmacogenetics 2000; 10: 25–33. Search in Google Scholar

47. Lee AJ, Cai MX, Thomas PE, Conney AH, Zhu BT. Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology 2003; 144: 3382–98. Search in Google Scholar

Received: 2005-4-19
Accepted: 2005-4-25
Published Online: 2011-9-21
Published in Print: 2005-7-1

©2005 by Walter de Gruyter Berlin New York